原发性铂类无治疗间期与BRCA1/2突变状态对复发性卵巢癌患者治疗及生存的影响
多中心社区回顾性观察队列研究纳入750例III-IV期高级别卵巢癌患者,评估原发性铂类无治疗间期(PFI)与BRCA状态对总生存(OS)的影响。中位OS为41.4个月(95%CI 39.0-48.3个月),原发性PFI≥6个月者在二线和三线治疗时OS显著增加(P<0.0001和P=0.002),BRCA突变者生存有改善趋势但未达统计学显著。
要点
- 原发性PFI≥6个月者二线及三线治疗时OS显著优于PFI<6个月者。
- BRCA突变患者跨多线治疗生存有改善趋势,但未达统计学显著。
- 仅36%患者BRCA状态已知,其中16%携带BRCA突变。
核心结论
- 原发性PFI≥6个月的患者在多线治疗中表现出更好的结局。
- BRCA状态已知者占36%,BRCA突变患者表现出原发性复发延迟和临床结局改善的趋势。
研究设计与样本
- 多中心、社区为基础的回顾性观察队列研究,数据来自美国社区肿瘤网络电子健康记录。
- 共审查750份患者病历,纳入成人III-IV期高级别卵巢癌患者。
- 267例患者BRCA检测状态已知,其中16%携带BRCA突变。
主要发现
- 在已识别复发患者中,41%的原发性PFI<6个月,59%的原发性PFI≥6个月。
- 二线患者中59%接受了三线治疗,三线患者中60%在观察期内接受了四线治疗。
- 全人群自原发性治疗开始的中位OS为41.4个月(95%CI 39.0-48.3个月)。
- 原发性PFI≥6个月者在二线和三线治疗时中位OS显著增加(P<0.0001和P=0.002)。
- BRCA突变患者跨多线治疗生存有改善趋势,但未达统计学显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To understand the relationship between primary platinum-free interval (PFI), BRCA mutation status, and overall survival (OS) in patients with recurrent ovarian cancer receiving multiple lines of therapy in a multicenter, community-based, retrospective observational cohort study of adult patients with stage III-IV high-grade ovarian cancer. METHODS: Data were retrospectively obtained from the electronic health record (EHR) of a US community oncology network, including patient characteristics, subsequent treatments, primary PFI, and BRCA status. OS was analyzed by the Kaplan-Meier method, stratified by primary PFI and BRCA status. RESULTS: 750 patient charts were reviewed. BRCA testing status was known in 267 patients (16% BRCA mutation). Among patients with identified recurrent disease, 41% had a primary PFI <6months and 59% had a primary PFI ≥6months. Of second-line patients, 59% received third-line therapy, and 60% of third-line patients received fourth-line therapy within the period of observation. Median OS from the start of primary treatment for the entire population was 41.4months (95% CI, 39.0-48.3months). Median OS was significantly increased in patients with primary PFI ≥6months at second-line and third-line (P<0.0001 and P=0.002, respectively). Survival was observed to be increased among patients with BRCA mutations across multiple treatment lines, although this was not statistically significant. CONCLUSIONS: Patients with a primary PFI ≥6months demonstrated improved outcomes over multiple lines of therapy. BRCA status was known in 36% of patients, and those patients with a BRCA mutation demonstrated a trend toward delayed primary recurrence and improved clinical outcomes.
引用
- Bookman MA, Tyczynski JE, Espirito JL, et al. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer. Gynecol Oncol. 2017. PMID: 28454659. doi:10.1016/j.ygyno.2017.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。